Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Quotient Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Quotient Sciences will support the GMP manufacture and first clinical pharmacokinetic (PK) study for EMPLI03 (buprenorphine) using its unique Translational Pharmaceutics® platform for the treatment of moderate to severe pain.
Brand Name : Empli03
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 29, 2022
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Quotient Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Emplicure AB Announce Completion of Phase I PK Study for EMPLI03 with Quotient Sciences
Details : EMPLI03, intended for the treatment of moderate to severe pain. 12 healthy subjects were given a single dose of an oral buccal tablet and blood samples were collected for analysis of Buprenorphine.
Brand Name : EMPLI03
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 27, 2022
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
